Skip to main content
OpenTrials
Completed

NCT Number: NCT02397876

Partially Hydrolyzed Whey Formula in Cow's Milk Allergic Patients

Cow's milk (CM) allergy is the most common food allergy in children, affecting 2-3% of infants. In formula-fed infants with CM allergy, extensively hydrolyzed or amino acid-based infant formulas are typically recommended. These formulas are expensive and not palatable. For older patients with CM allergy, the standard of care is avoidance of all CM products. The investigators cared for a CM allergic patient who was able to tolerate partially hydrolyzed whey formula (pHWF), which tastes better and is less expensive than extensively hydrolyzed or amino-acid based formulas. There are likely other subjects who could similarly tolerate pHWF. Furthermore, it is possible that taking pHWF could accelerate tolerance of CM. The investigators aim to identify characteristics of CM allergic subjects who can tolerate pHWF and assess the degree to which taking pHWF accelerates CM tolerance.

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 month–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Icahn School of Medicine at Mount Sinai

New York, 10029, United States

About this study

Specifically, subjects who have CM allergy will be enrolled. The investigators will perform an oral food challenge (OFC) to pHWF in each subject. Subjects who pass the challenge will be placed on pHWF for 2 years. Subjects who do not pass the challenge will receive routine care. The investigators will perform allergy skin testing, specific IgE measurement, other serologic assays, and longitudinal OFCs to profile subject characteristics in the two groups at baseline and over time.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age 0.5-18 years old
  • positive skin prick tests (SPT) or detectable serum milk specific IgE and a history of an allergic reaction to milk within 6 months before study screening; or milk-specific IgE level or SPT highly predictive for clinical reactivity (if ≤ 2 years old, sIgE >2 kU/L; if > 2 years old, a level >5 kU/L; SPT wheal diameter ≥ 3 mm)
  • a clinical reaction during the cows milk oral food challenge

Exclusion criteria

  • negative SPT and undetectable milk-specific sIgE
  • unstable asthma, allergic rhinitis, or atopic dermatitis
  • milk-induced eosinophilic gastroenteropathy
  • recent reaction to partially hydrolyzed whey formula
  • history of severe anaphylaxis with hypotension to cows milk
  • participation in any interventional study for the treatment of food allergy in the 6 months prior to screening visit
  • inhalant allergent immunotherapy that has not yet reached maintenance dosing
  • inability to discontinue antihistamines for skin testing, OFC
  • any systemic therapy which in the judgment of the investigator could be immunomodulatory in the 12 months prior to visit 1 (xolair, rituximab, chronic steroids, etc)
  • investigational drug use 90 days prior to visit 1 or intention to use during study period
  • the presence of any medical condition that the investigator deems incompatible with participation in the trial.
  • unable to understand and speak English

Treatment and study plan

Partially Hydrolyzed Whey formula

Other

Patients who tolerate partially hydrolyzed whey formula will be continued on this formula for two years. Patients who do not tolerate the formula will be continued on their prior diet of cows milk avoidance.

Other names: Gerber Good Start Formula

Primary outcomes

  1. Prevalence of partially hydrolyzed whey formula tolerance

    Time frame: Day 1

    Prevalence of partially hydrolyzed whey formula tolerance in cow's milk allergic patients - Identify patients who are cow's milk allergic but can tolerate a partially hydrolyzed whey formula

Secondary outcomes

  1. Time to resolution of cows milk allergy

    Time frame: up to 2 years

    Determine if ingestion of partially hydrolyzed whey formula accelerates the resolution of allergy to cow's milk.

Sponsors and collaborators

Lead sponsor

Icahn School of Medicine at Mount Sinai

Other

Collaborators

  • Société des Produits Nestlé (SPN)

Registry information

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Mar 25, 2015
Registry last updated
Dec 7, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.